Ovarian cancer remains the most deadly malignancy. Targeting angiogenesis is a particulariy attractive strategy because of the presumed genetic stability of endothelial cells. This is best illustrated by recent successes of anti-angiogenic therapy (e.g., bevacizumab) in patients with solid tumors. However, despite initial responses, most patients eventually develop tumor progression resulting in their demise. Therefore, new anti-angiogenesis therapeutic strategies are needed. The overall goal of this project is to develop novel nanoparticle-based strategies to target the tumor vasculature specifically. We propose to utilize two types of biocompatible therapeutic nanoparticles (chitosan and gold nanoshell nanoparticles) for the delivery of therapeutic payloads (e.g., siRNA) or near-infrared (NIR) laser mediated thermal ablation. These platforms are supported by Integrated approaches for selective delivery into the tumor vasculature using either rationally designed multi-stage carriers or surface ligands (thioaptamers) selected from screening libraries based on selective binding. Using genomic approaches, we have identified novel candidate target genes in ovarian cancer vasculature that will be targeted using RNAi approaches (Aim 1) because many are difficult to inhibit with small molecules or monoclonal antibodies. In our preliminary findings, we have identified thiophosphate oligonucleotide aptamers (thio-aptamers) that selectively bind to tumor, but not to normal endothelial cells based on counter selection strategies using freshly isolated endothelial cells from human ovarian cancer or normal ovaries.
In Aim 1, we will develop thioaptamertargeted nanoparticles for selective delivery of therapeutic siRNA. On the basis of our preliminary findings regarding the critical role of size and shape in vascular localization of nanoparticles, we will pursue rational design of nanoparticles for targeting the tumor vasculature in Aim 2. Gold-based nanoshells offer unique opportunities for thermal ablation using NIR light.
In Aim 3, we will develop and characterize novel approaches for thermal ablation of ovarian cancer vasculature using targeted gold nanoshells. All three aims are complementary to each other and findings of this study should allow the design and translation of new therapeutic approaches for women with ovarian cancer.
|Ornelas, Argentina; McCullough, Christopher R; Lu, Zhen et al. (2016) Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16:824|
|Zacharias, Niki M; McCullough, Christopher R; Wagner, Shawn et al. (2016) Towards Real-time Metabolic Profiling of Cancer with Hyperpolarized Succinate. J Mol Imaging Dyn 6:|
|Hatakeyama, Hiroto; Wu, Sherry Y; Mangala, Lingegowda S et al. (2016) Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 1402:189-97|
|Hosoya, Hitomi; Dobroff, Andrey S; Driessen, Wouter H P et al. (2016) Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A 113:1877-82|
|Tasciotti, Ennio; Cabrera, Fernando J; Evangelopoulos, Michael et al. (2016) The Emerging Role of Nanotechnology in Cell and Organ Transplantation. Transplantation 100:1629-38|
|Au Yeung, Chi Lam; Co, Ngai-Na; Tsuruga, Tetsushi et al. (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150|
|Zhou, Min; Melancon, Marites; Stafford, R Jason et al. (2016) Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. J Nucl Med 57:1778-1783|
|Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :|
|Mi, Yu; Wolfram, Joy; Mu, Chaofeng et al. (2016) Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res 113:92-99|
|Rupaimoole, R; Ivan, C; Yang, D et al. (2016) Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35:4312-20|
Showing the most recent 10 out of 308 publications